ClinicalTrials.gg

Program

rapcabtagene autoleucel

Also written as “Rapcabtagene autoleucel”, “rapcabtagene autoleucel (YTB323)” and “YTB323”.

In Novartis’s pipeline, CD19 CAR-T. Its studies are mostly in Lupus Nephritis · Multiple Sclerosis, Chronic Progressive · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Arthritis, Rheumatoid · Scleroderma, Diffuse, led by Novartis.

Furthest: phase 2, since Feb 27, 20238 company-led studies, 7 open or runningNext primary completion: Feb 14, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis87 open or runningphase 2since Feb 27, 2023Feb 27, 2023Feb 14, 2028phase 2 · NCT06581198
  • Named in Novartis’s own pipeline as YTB323 (rapcabtagene autoleucel), phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2023First study: phase 2 study in Lupus Erythematosus, SystemicFirst studyNCT05798117 · 21 enrolled · Australia, France, Germany and more
  2. Aug 23, 2024Phase 2 study in Lupus Erythematosus, SystemicNCT06581198 · 179 enrolled · United States, Argentina, Australia and more
  3. Sep 26, 2024Phase 2 study in Multiple SclerosisNCT06617793 · 28 enrolled · Australia, France, Germany and more
  4. Oct 22, 20242 phase 2 studiesNCT06655896, NCT06665256
  5. Nov 4, 2024Phase 2 study in Multiple Sclerosis, Chronic ProgressiveNCT06675864 · 28 enrolled · Australia, Canada, France and more
  6. Mar 7, 2025Phase 2 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT06868290 · 126 enrolled · United States, Brazil, Israel and more
  7. Jun 24, 2025Phase 2 study in Arthritis, RheumatoidNCT07048197 · 27 enrolled · France, Germany, Singapore and more

Ahead

  1. Feb 14, 2028Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06581198
  2. Nov 1, 2028Primary completion: phase 2 study in Arthritis, RheumatoidNCT07048197
  3. Nov 30, 2028Primary completion: phase 2 study in Scleroderma, DiffuseNCT06655896
  4. Mar 9, 2029Primary completion: phase 2 study in MyositisNCT06665256

TargetBeta

“CD19 CAR-T”the company's pipeline, read by Claude · source
“A preparation of autologous T-lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, ”NCIt, by rule

Other programs on CD19

ProgramCompanyFurthest phaseStudies
blinatumomabruleAmgenphase 429
inebilizumabruleAmgenphase 419
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
axicabtagene ciloleucelruleGilead Sciencesphase 310
surovatamigAstraZenecaphase 310
lisocabtagene maraleucelruleBristol-Myers Squibbphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
obexelimabzenas-biopharma-usa-llcphase 37
Autologous Anti-CD19 CAR-T Cells CABA-201rulecabaletta-biophase 36
zolacabtagene autoleucelBristol-Myers Squibbphase 36
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 32
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07048197Arthritis, Rheumatoid · France, Germany, Singapore and more2Active, not recruitingNov 1, 202827
NCT06868290Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · United States, Brazil, Israel and more2Active, not recruitingJun 7, 2029126
NCT06675864Multiple Sclerosis, Chronic Progressive · Australia, Canada, France and more2Active, not recruitingJun 14, 203028
NCT06665256Myositis · United States, Australia, Brazil and more2Active, not recruitingMar 9, 202921
NCT06655896Scleroderma, Diffuse · United States, Argentina, Australia and more2Active, not recruitingNov 30, 202896
NCT06617793Multiple Sclerosis · Australia, France, Germany and more2Active, not recruitingAug 7, 203028
NCT06581198Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2Active, not recruitingFeb 14, 2028179
NCT05798117Lupus Erythematosus, Systemic · Australia, France, Germany and more2CompletedSep 24, 202621

How it is read

Names in the registry

  • “Rapcabtagene autoleucel”, 3 entries
  • “rapcabtagene autoleucel (YTB323)”, 2 entries
  • “rapcabtagene autoleucel”, 2 entries
  • “YTB323”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.